1. History
- Key HPI questions: Onset, location, and character of abdominal pain (most common symptom, present in ~80% of acute cases); timing relative to recent surgery, hospitalization, or abdominal inflammatory events [1-2]
- Symptom characterization: Upper abdominal pain, often described as colicky or constant; pain disproportionate to exam findings is a classic feature [1]
- Timing/triggers: Recent abdominal surgery (splenectomy, bariatric, colectomy), pancreatitis, diverticulitis, appendicitis, IBD flare, recent OCP use, pregnancy/postpartum [2-3]
- Associated symptoms: Nausea, vomiting, anorexia, postprandial fullness, fever, abdominal distension, diarrhea, GI bleeding, jaundice [1-2][4]
- Important negatives: Absence of hematochezia, hematemesis, melena; no prior VTE history; no known liver disease; no weight loss or constitutional symptoms
2. Alarm Features
- Abdominal pain out of proportion to exam — hallmark of mesenteric ischemia from thrombus extension [1][5]
- Fever with sepsis/bacteremia → suspect pylephlebitis (septic portal vein thrombosis) [1]
- Rebound tenderness, guarding, peritoneal signs → bowel infarction [2][4]
- Elevated serum lactate, leukocytosis, bloody diarrhea/hematochezia → intestinal ischemia [1][5]
- Hematemesis or melena → variceal hemorrhage from portal hypertension [6]
- Rapid-onset ascites, hepatomegaly, or acute liver failure (if extensive/rapid thrombosis) [3]
- Intestinal ischemia carries 10–20% mortality and requires urgent anticoagulation and multidisciplinary management [5]
3. Medications
- Relevant contributors: Oral contraceptives/exogenous estrogens, hormone replacement therapy [1-2]
- Nonselective beta-blockers — meta-analysis showed increased PVT incidence in cirrhosis (OR 4.62), though confounded by variceal severity [3]
- Treatment options:
- LMWH (enoxaparin) — first-line for acute PVT; avoid long-term UFH (risk of HIT, which is notably higher in this population) [3][7]
- DOACs (rivaroxaban, dabigatran) — increasingly used; comparable recanalization to LMWH, lower bleeding than warfarin; reasonable in CTP class A and B cirrhosis [5][7]
- Warfarin (VKA) — effective but INR monitoring unreliable in cirrhosis; less convenient [5]
- Contraindicated/caution: UFH long-term (HIT risk); DOACs in CTP class C cirrhosis (limited data); anticoagulation when platelets <50,000/μL requires individualized risk-benefit assessment [1][5]
4. Diet
- No specific dietary triggers for PVT
- In cirrhotic patients with ascites: sodium restriction (<2 g/day)
- Adequate hydration to avoid hemoconcentration, particularly in hypercoagulable states
- Long-term: address metabolic syndrome and obesity, which are independent risk factors for PVT in cirrhosis [3]
5. Review of Systems
- GI: Abdominal pain, nausea, vomiting, diarrhea, bloody stools, hematemesis, early satiety, jaundice
- Constitutional: Fever, weight loss, night sweats (malignancy screen), fatigue
- Hematologic: Prior DVT/PE, easy bruising, petechiae (MPN, thrombocytopenia)
- Hepatic: Ascites, peripheral edema, pruritus, dark urine
- Gynecologic: OCP use, pregnancy, recent postpartum state
- Dermatologic: Erythromelalgia, aquagenic pruritus (MPN clues)
6. Collateral History and Family History
- Family history of VTE, thrombophilia, or myeloproliferative neoplasms (MPNs)
- Personal history of spontaneous VTE at unusual sites (cerebral, splanchnic)
- History of recurrent pregnancy loss (antiphospholipid syndrome)
- Social context: alcohol use (cirrhosis risk), smoking, IV drug use (pylephlebitis)
- Recent travel, immobilization, or hospitalization
7. Risk Factors
8. Differential Diagnosis
- Mesenteric arterial ischemia — more acute, arterial source; CT angiography differentiates
- Budd-Chiari syndrome (hepatic vein thrombosis) — hepatomegaly, ascites, caudate hypertrophy; distinct imaging pattern [3]
- Malignant portal vein invasion (HCC, cholangiocarcinoma, pancreatic cancer) — tumor thrombus shows arterialization on contrast imaging [1][9]
- Acute pancreatitis — can both mimic and cause PVT; lipase/amylase help differentiate
- Bowel obstruction — dilated loops, air-fluid levels; no filling defect in portal vein
- Hepatic abscess/pylephlebitis — septic PVT with gas in portal vein, bacteremia [1]
- Biliary obstruction — jaundice from portal biliopathy in chronic PVT can mimic choledocholithiasis [6]
9. Past Medical History
- Cirrhosis (any etiology) — prevalence of PVT ranges from 1% (compensated) to 20% (transplant candidates) [1][3]
- Prior VTE events (DVT, PE, cerebral venous thrombosis)
- Known MPN (polycythemia vera, essential thrombocythemia, myelofibrosis)
- Prior abdominal surgery (especially splenectomy)
- IBD, pancreatitis, or other intra-abdominal inflammatory conditions
- HCC or other hepatobiliary malignancy
- Known thrombophilia or antiphospholipid syndrome
10. Physical Exam
- Vital signs: Fever (pylephlebitis, ischemia), tachycardia, hypotension (sepsis, hemorrhage)
- Abdominal exam:
- Distension (ascites, ileus)
- Tenderness — often mild relative to pain severity ("pain out of proportion to exam") [1]
- Guarding/rebound → peritonitis from bowel infarction
- Hepatomegaly (67% at diagnosis), splenomegaly [2-3]
- Stigmata of chronic liver disease: Spider angiomata, palmar erythema, caput medusae, jaundice, gynecomastia
- Signs of portal hypertension: Ascites, splenomegaly, caput medusae, hemorrhoids
- Lower extremity edema — if IVC involvement
- Rectal exam: Occult or frank blood (ischemia, variceal bleed)
11. Lab Studies
12. Imaging
- First-line: Doppler ultrasound — sensitivity 73–93%, specificity 92–99%; demonstrates hyperechoic intraluminal material, absent/diminished flow, portal vein dilation [1][5][10]
- CT abdomen/pelvis with IV contrast — gold standard for comprehensive evaluation; ~90% accuracy; assesses thrombus extent into mesenteric veins, bowel viability, and differentiates bland vs. tumor thrombus (arterialized thrombus = HCC) [1]
- Acute PVT: central lucency within expanded, sharply defined vein
- Chronic PVT: portal cavernoma (serpiginous collaterals replacing main portal vein), splenomegaly, varices [1]
- MRI with contrast — comparable accuracy; useful when CT contrast is contraindicated; specificity 98% [10]
- Imaging unnecessary: Routine screening in asymptomatic compensated cirrhosis is not recommended [5]
The NCCN diagnostic algorithm for splanchnic vein thrombosis outlines the stepwise approach:
13. Special Tests
- JAK2 V617F mutation testing — highly specific (90–95%) for MPN diagnosis; should be obtained in all non-cirrhotic PVT [1]
- CALR mutation — rare but relevant in JAK2-negative suspected MPN [4]
- Bone marrow biopsy — if MPN suspected based on labs/mutation testing
- Thromboelastography (TEG) — emerging tool to assess bleeding risk in cirrhotic patients being considered for anticoagulation [5]
- EGD — recommended in chronic PVT to assess for esophageal/gastric varices; should be performed before initiating anticoagulation in cirrhotic patients [1]
- Hepatic venography — reserved for uncertain cases; "spider web" pattern of collaterals is characteristic of hepatic vein thrombosis [3]
14. ECG
- ECG is not a primary diagnostic tool for PVT
- Obtain if hemodynamically unstable to rule out concurrent cardiac pathology
- Tachycardia (sinus) expected in sepsis, hemorrhage, or pain
- No PVT-specific ECG findings
15. Assessment
Severity stratification (per AGA/AASLD framework): [5]
- Recent (<6 months), minimally occlusive (<50%) → high spontaneous recanalization rate (~40%); may observe
- Recent (<6 months), >50% occlusive or extensive → significant hemodynamic impact (94% flow reduction at 50% occlusion per Poiseuille's law); anticoagulation recommended
- Chronic (>6 months) with cavernous transformation → low recanalization potential; manage portal hypertension complications
Key distinctions
- Cirrhotic vs. non-cirrhotic PVT — different risk profiles, workup, and management approaches [11]
- Bland thrombus vs. tumor thrombus — critical to differentiate on imaging; tumor thrombus shows arterial enhancement [1]
- Complications: intestinal ischemia/infarction, portal hypertension, variceal bleeding, portal biliopathy, hepatic decompensation [2][5]
16. Treatment Plan
The NCCN treatment algorithm by location and acuity:
Acute PVT — Initial management
- With intestinal ischemia: Urgent therapeutic anticoagulation (LMWH preferred initially); surgical consultation for bowel infarction; consider catheter-directed thrombectomy/thrombolysis if no improvement [3-5]
- Without ischemia, non-cirrhotic: Therapeutic anticoagulation should be started immediately per Baveno VII; LMWH → transition to DOAC or VKA [1][7]
- Without ischemia, cirrhotic: Individualized — anticoagulate if >50% occlusive, involves main PV or mesenteric veins, or transplant candidate [3][5]
Anticoagulation options: [5][7]
- LMWH — best evidence; higher recanalization than warfarin (OR 8.4 vs 2.2); preferred in transplant candidates (short half-life, procedural flexibility)
- DOACs — rivaroxaban or dabigatran; meta-analysis shows 87% vs 44% recanalization vs no treatment; convenient; reasonable in CTP A–B
- Warfarin — effective but INR unreliable in cirrhosis; cumbersome monitoring
Duration: [1][5]
- Reversible etiology (surgery, pancreatitis): 3–6 months
- Permanent prothrombotic state (MPN, antiphospholipid syndrome): indefinite
- Cirrhosis with PVT: 6 months minimum; continue until transplant if listed; reimage every 3 months
- Chronic PVT with cavernoma: anticoagulation generally not beneficial; focus on portal hypertension management (beta-blockers, variceal banding) [3-4]
Interventional options
- TIPS — consider in cirrhotic patients with symptomatic portal hypertension and PVT; achieves high recanalization rates (81% in prospective data) [12]
- Catheter-directed thrombolysis/thrombectomy — salvage for failed anticoagulation or severe acute presentations [4]
17. Disposition
- Admit if:
- Signs of intestinal ischemia (pain out of proportion, elevated lactate, peritoneal signs) [5]
- Hemodynamic instability, sepsis, or active GI bleeding
- Need for IV anticoagulation initiation
- Acute symptomatic PVT with significant thrombus burden
- Pylephlebitis requiring IV antibiotics
- Observation may be appropriate for:
- Stable, symptomatic acute PVT without ischemia while initiating anticoagulation
- Incidental PVT requiring further workup
- Discharge criteria:
- Hemodynamically stable, tolerating oral intake
- Pain controlled, no signs of ischemia
- Anticoagulation plan established (DOAC or LMWH bridge)
- Outpatient follow-up arranged with gastroenterology/hepatology and hematology
- Specialist consultation triggers: Surgery (bowel ischemia/infarction), interventional radiology (thrombectomy/TIPS), hematology (thrombophilia/MPN workup), hepatology (cirrhotic patients, transplant candidates) [3][5]
18. Follow Up / Return Precautions
- Imaging follow-up: Cross-sectional imaging (CT or MRI) every 3 months while on anticoagulation to assess recanalization [5]
- EGD: Perform to screen for varices in chronic PVT or cirrhotic patients; initiate prophylaxis (beta-blockers or banding) as indicated [1]
- Anticoagulation monitoring: If on warfarin, INR checks; if on LMWH, anti-Xa levels as needed; DOACs require renal/hepatic function monitoring
- Recurrence risk: Up to 38% rethrombosis after anticoagulation withdrawal; continue anticoagulation in transplant candidates even after recanalization [5]
- Return precautions — instruct patients to seek immediate care for:
- Worsening or new abdominal pain
- Bloody stools, hematemesis, or melena
- Fever, chills, or signs of infection
- Lightheadedness, syncope, or signs of bleeding on anticoagulation
- New-onset leg swelling, chest pain, or dyspnea (concurrent VTE)
- Expected course: With anticoagulation, recanalization rates range from 40–87% depending on agent and thrombus characteristics; spontaneous recanalization without treatment occurs in ~40% of cirrhotic patients [5]
References
1. ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation. — Simonetto DA, Singal AK, Garcia-Tsao G, et al. The American Journal of Gastroenterology. 2020.
2. Review article: portal vein obstruction – epidemiology, pathogenesis, natural history, prognosis and treatment. — Kumar A, Sharma P, Arora A. Alimentary Pharmacology & Therapeutics. 2015.
3. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. — Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Hepatology. 2021.
4. Cancer-Associated Venous Thromboembolic Disease. — Updated 2026-05-05. National Comprehensive Cancer Network.
5. AGA Clinical Practice Update on Management of Portal Vein Thrombosis in Patients With Cirrhosis: Expert Review. — Davis JPE, Lim JK, Francis FF, Ahn J. Gastroenterology. 2025.
6. Hepatic Issues and Complications Associated With Inflammatory Bowel Disease: A Clinical Report From the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees. — Saubermann LJ, Deneau M, Falcone RA, et al. Journal of Pediatric Gastroenterology and Nutrition. 2017.
7. Portal Vein Thrombosis: Diagnosis, Management, and Endpoints for Future Clinical Studies. — Elkrief L, Hernandez-Gea V, Senzolo M, et al. The Lancet. Gastroenterology & Hepatology. 2024.
8. Thrombophilia Testing and Venous Thrombosis. — Connors JM. The New England Journal of Medicine. 2017.
9. Portal Vein Thrombosis: State-of-the-Art Review. — Boccatonda A, Gentilini S, Zanata E, et al. Journal of Clinical Medicine. 2024.
10. Diagnostic Performance of Ultrasound, Computed Tomography and Magnetic Resonance Imaging in Portal Vein Thrombosis: A Systematic Review With Meta-Analysis. — Girardi L, Zarka F, Pradier M, et al. Thrombosis Research. 2025.
11. Contemporary Management of Portal Vein Thromboses in Patients With and Without Cirrhosis. — Shenoy A, Davis JPE. Current Opinion in Gastroenterology. 2025.
12. Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study. — Lv Y, Bai W, Li K, et al. The American Journal of Gastroenterology. 2021.